HM THE KING VISITS PULEVA BIOTECH ON THE 10TH ANNIVERSARY OF THE DEVELOPMENT OF PULEVA OMEGA 3
- His Majesty King Juan Carlos visited in Granada the pioneering biotechnology centre in the research and development of functional foods within Europe.
- PULEVA Biotech has developed the necessary technical know-how with which to produce functional foods that contain Eupoly Omega 3®, an oil rich in Omega 3 (Epa-Dha) with pysiologically active levels. With a current annual production of 500.000 kilos and exports representing 40%, the biotechnology centre has become the world leader in the commercialisation of LC-Omega 3 for functional foods.
- PULEVA Omega 3, whose properties in the prevention of cardiovascular risk factors have been scientifically proven, has become the most widely consumed functional food enriched with Omega-3 fatty acids in the world, with more than 500 million litres sold.
 |
Photo
gallery of the visit |
HM The King visited the various departments of the research centre accompanied by Mr. Gregorio Jiménez, President of PULEVA Biotech; Mr. Antonio Hernández Callejas, President of the Ebro Puleva Group; Mr. Juan Carlos de Gregorio, Chief Executive Officer of PULEVA Biotech and Mr. Jesús Jiménez, Director General of PULEVA Biotech; amongst other attending company managers and directors.
PULEVA Biotech, worldwide benchmark company in the production and sale of LC-Omega 3
PULEVA Biotech, biotechnology company part of the Ebro Puleva Group, leading Spanish food company, is a pioneer in the research, manufacture and commercialisation of new products based on natural ingredients with beneficial effects upon health with the objective of improving quality of life through a diet better adapted to the needs of the population.
This research centre has developed the technical know how to produce functional foods containing Eupoly Omega 3®, an oil rich in Omega 3 (Epa-Dha) with physiologically active levels.
The development in 1997 of PULEVA Omega 3, milk enriched with Omega 3 fatty acids, was one of the main milestones of PULEVA since its inception.
In 2004, PULEVA Biotech began international expansion of its commercialisation of the Omega 3 oils. With a current production of 500.000 kilos per annum, exports of 40% and a presence on all continents, the biotechnology centre has become the world leader in the sale of LC-Omega 3, principally for functional dairy foods.
PULEVA Omega 3, ten years contributing to the prevention of cardiovascular risk factors
According to data from the World Health Organisation (WHO), cardiovascular disease is the leading cause of death in the world, with the main risk factors being high levels of cholesterol, high blood pressure, obesity, smoking, diabetes, hereditary factors and little or no regular physical exercise.The daily consumption of long chain Omega-3 polyunsaturated fatty acids, as part of a healthy lifestyle, helps to maintain good cardiovascular health and reduces the risk of suffering from cardiovascular diseases, according to data from the North American Food and Drugs Agency (FDA). PULEVA Omega 3, developed by PULEVA Biotech, has spent 10 years contributing to the prevention of cardiovascular risk factors. This milk drink is enriched with Omega-3 fatty acids and has been scientifically proven through 8 clinical trials carried out with the product - 3 with healthy individuals and 5 with patients with cardiovascular diseases– which showed that the daily consumption of 500 ml of PULEVA Omega 3 has a beneficial effect upon 5 cardiovascular risk factors, amongst them, total cholesterol and LDL-cholesterol, the reduction of high levels of triglycerides and a reduction in levels of homocysteine. Studies that have also been published in the most prestigious international science magazines, such as Clinical Nutrition (2003), Agrofood Industry Hi-tech (2003), Nutrafoods (2003), Nutrition (2004) y Human Nutrition and Metabolism (2005).
PULEVA Omega 3 is an enriched milk that has strong consumer backing. With 500 million litres sold, it has become the most widely consumed functional food enriched with Omega-3 fatty acids in the world.
About PULEVA Biotech
The PULEVA Biotech research centre plays a key role on a national and international level in both the research and development of functional foods as well as the provision of R+D services to third parties.An awareness of the nutritional needs of the population drives PULEVA Biotech to research and develop first class healty foods for the entire family. PULEVA Biotech's strategy, based on a permanent policy of innovation, is oriented towards the search for and development of new bioactive compounds which, incorporated within food, contribute to the prevention of diseases relating to the cardiovascular system, obesity or diabetes. A principle which frames the R+D activity of each and every one of the 146 professionals who form part of PULEVA Biotech, 72 of whom are researchers and more than 30 of whom bear the title of Doctor.